CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.12% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Apellis Pharmaceuticals, Inc. - APLS CFD

29.87
0.81%
Market Trading Hours* (UTC) Opens on Tuesday at 14:30

Tue - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.12
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023346 %
Charges from full value of position ($-0.23)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
-0.023346%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001124 %
Charges from full value of position ($0.01)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
0.001124%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 50.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 29.63
Open 29.82
1-Year Change -33.66%
Day's Range 29.56 - 30.09
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jan 17, 2025 29.87 0.19 0.64% 29.68 30.16 29.53
Jan 16, 2025 29.63 0.60 2.07% 29.03 30.03 29.03
Jan 15, 2025 28.99 1.04 3.72% 27.95 30.05 27.95
Jan 14, 2025 27.62 -1.08 -3.76% 28.70 29.07 27.59
Jan 13, 2025 28.53 0.06 0.21% 28.47 29.58 27.54
Jan 10, 2025 27.35 -2.61 -8.71% 29.96 30.25 27.29
Jan 8, 2025 32.93 -1.02 -3.00% 33.95 34.09 32.91
Jan 7, 2025 34.55 0.19 0.55% 34.36 35.46 33.78
Jan 6, 2025 34.32 0.84 2.51% 33.48 35.07 33.22
Jan 3, 2025 33.40 0.62 1.89% 32.78 34.04 32.78
Jan 2, 2025 33.10 1.37 4.32% 31.73 33.42 31.73
Dec 31, 2024 31.86 -0.05 -0.16% 31.91 32.59 31.36
Dec 30, 2024 31.86 -0.19 -0.59% 32.05 32.36 31.83
Dec 27, 2024 32.63 0.16 0.49% 32.47 33.26 32.36
Dec 26, 2024 32.86 0.01 0.03% 32.85 33.16 32.26
Dec 24, 2024 33.21 0.39 1.19% 32.82 33.30 32.44
Dec 23, 2024 33.16 -0.15 -0.45% 33.31 33.34 32.72
Dec 20, 2024 33.13 0.16 0.49% 32.97 34.20 32.81
Dec 19, 2024 33.06 -0.82 -2.42% 33.88 33.99 32.80
Dec 18, 2024 33.96 -0.07 -0.21% 34.03 35.59 33.70

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
Leverage
2:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company also develops APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration, as well as is in Phase I/II clinical trial for acute respiratory distress syndrome. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam''s base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Industry: Biopharmaceuticals

100 Fifth Avenue
WALTHAM
MASSACHUSETTS 02451
US

People also watch

BTC/USD

104,252.25 Price
+4.290% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

US100

21,441.70 Price
+1.820% 1D Chg, %
Long position overnight fee -0.0233%
Short position overnight fee 0.0011%
Overnight fee time 22:00 (UTC)
Spread 7.0

ETH/USD

3,435.27 Price
+3.830% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

Gold

2,703.08 Price
-0.430% 1D Chg, %
Long position overnight fee 0.0056%
Short position overnight fee -0.0138%
Overnight fee time 22:00 (UTC)
Spread 0.60

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading